Efficacy and safety of intravenous meropenem and tobramycin versus ceftazidime and tobramycin in cystic fibrosis

BackgroundCystic fibrosis (CF) is characterized by chronic bacterial broncho-pulmonary infection. Although intravenous (IV) antibiotic therapy is regarded as standard treatment in CF, only few randomised trials comparing different antibiotic compounds exist.MethodsWe report on a prospective multicenter interventional trial of IV meropenem (120 mg/kg/day) or IV ceftazidime (200–400 mg/kg/day), each administered together with IV tobramycin (9–12 mg/kg/day). Outcome measures were changes in lung function, microbiological sputum burden and blood inflammatory marker. Liver and renal function values were measured to assess safety.ResultsOne hundred eighteen patients (59/59) were included into the study with the following indications: first infection of P. aeruginosa (n = 6), acute pulmonary exacerbation (n = 34) and suppression therapy of chronic P. aeruginosa colonization (n = 78). Both treatments improved lung function measures, bacterial sputum burden and CRP levels with no differences between treatment groups observed. A significant higher elevation for alkaline phosphatase (p < 0.0001) was observed for patients in the meropenem/tobramycin group.ConclusionsIV antibiotic therapy in CF patients with meropenem/tobramycin is as effective as with ceftazidime/tobramycin regarding lung function, microbiological sputum burden and systemic inflammatory status. Hepato-biliary function should be monitored carefully during IV treatment, possibly important in CF patients with pre-existing liver disease.